Comparative Pharmacology
Head-to-head clinical analysis: CROLOM versus NASALCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROLOM versus NASALCROM.
CROLOM vs NASALCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CROLOM is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors, blocking estrogen-mediated signaling in target tissues, thereby inhibiting growth of hormone-sensitive breast cancer cells.
Cromolyn sodium stabilizes mast cells by inhibiting the release of histamine and other mediators of inflammation from sensitized mast cells. The exact molecular mechanism is not fully understood but may involve inhibition of calcium ion influx into mast cells.
2 capsules (each containing 40 mg cromolyn sodium) orally 4 times daily, 30 minutes before meals and at bedtime.
One spray (5.2 mg) into each nostril 3-4 times daily (maximum 6 times daily).
None Documented
None Documented
Terminal half-life 8-12 hours in normal renal function; extended to 20-30 hours in severe impairment
Terminal elimination half-life is 1-2 hours; clinically, due to local mast cell stabilization, systemic levels do not correlate with effect.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Primarily unchanged drug; renal excretion accounts for ~90% of elimination, with minor biliary/fecal excretion (<5%).
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer